VTVictor Terentiev

Victor Terentiev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victor Terentiev has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhancing accuracy of virtual kinase profiling via application of graph neural network to 3D pharmacophore ensembles

    by Alexey Ereshchenko, Sergei Evteev, Alexander Malyshev, Denis Adjugim, Fedor Sizov, Anna Pastukhova, Victor Terentiev, Petr Shegai, Andrey Kaprin, Yan Ivanenkov

    Kinase profiling is an essential step in both hit identification and selectivity evaluation. Since in vitro testing of large chemical libraries is costly and time-consuming, a computational approach can be applied to narrow down the reasonable chemical space. In this work, we collected data from several sources and prepared a curated, comprehensive database for training machine learning (ML) models to predict selectivity towards 75 kinases. We demonstrated the usefulness of this database by preparing several ML models with various molecular representations and model architectures. Among these, a graph neural network-based model enhanced by utilizing 3D pharmacophore ensembles showed the best performance. Finally, the developed model was applied to a library of in-stock compounds to facilitate kinase-focused drug discovery. Graphical abstract


  • Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)

    by Yan A. Ivanenkov, Alexander S. Malyshev, Victor A. Terentiev, Anastasia A. Korzhenevskaya, Sergei A. Evteev, Sergey Z. Vatsadze, Aleksei V. Medved’kO, Petr V. Shegai, Andrey D. Kaprin

    IntroductionThe ataxia telangiectasia mutated kinase (ATM) is key in coordinating the DDR signaling network essential for responding to double-strand breaks (DSBs). Several ATM inhibitors are being investigated for potential anticancer treatment in clinical trials.Areas coveredThis review aims to provide a comprehensive overview of patents and patent applications since 2003, with a particular focus on the structural properties, activity and efficacy of the claimed ATM kinase small-molecule inhibitors. The search was conducted using SciFinder, Cortellis Drug Discovery Intelligence Database, and Espacenet. After filtering, 44 records were identified for further analysis. This paper also discusses the recent progress in the clinical trials and development history.Expert opinionATM kinase is a promising target for cancer therapy. Small-molecule ATM kinase inhibitors hold significant potential in cancer treatment by enhancing the efficacy of existing DNA-damaging therapies. Patent analysis revealed that the majority of these compounds contain imidazo[4,5-c]quinolinone scaffold or its bioisosteric variations which are optimal in terms of good ATM inhibitory activity and selectivity over closely related enzymes. Clinical trials explore combinations with RT or DNA-targeted compounds like PARP inhibitors, which induce DSBs. The medicinal chemistry field anticipates that these therapeutic options will soon be available on the pharmaceutical market.


  • AlphaFold for a medicinal chemist: tool or toy?

    by Ya. A. Ivanenkov, S. A. Evteev, A. S. Malyshev, V. A. Terentiev, D. S. Bezrukov, A. V. Ereshchenko, A. A. Korzhenevskaya, B. A. Zagribelnyy, P. V. Shegai, A. D. Kaprin

    The development of novel small drug molecules is a complex and important cross-disciplinary task. In the early stages of development, chemoinformatics and bioinformatics methods are routinely used to reduce the cost of finding a lead compound. Among the tools of medicinal chemistry, docking and molecular dynamics occupy a special place. These methods are used to predict the possible mechanism of binding of a potential ligand to a protein target. However, in order to perform a docking study, it is necessary to know the spatial structure of the protein under investigation. Although databases of crystallographic structures are available, the three-dimensional representations of many protein molecules have not been reported. There is therefore a need to model such three-dimensional conformations. Several computer algorithms have been published to solve this problem. AlphaFold is considered by the scientific community to be the most effective approach to predicting the three-dimensional structure of proteins. However, the scope of its application in medicinal chemistry, especially for virtual screening, remains unclear. This review describes methods for predicting the three-dimensional structure of a protein and provides representative examples of the use of AlphaFold for the design and rational selection of potential ligands. Special attention is given to publications presenting the results of experimental validation of the approach. On the basis of performed analysis, the main problems in the field and possible ways to solve them are formulated. The bibliography includes 154 references.


  • Open Access

    Potential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality

    by Alex Zhavoronkov, Bogdan Zagribelnyy, Alexander Zhebrak, Vladimir Aladinskiy, Victor Terentiev, Quentin Vanhaelen, Dmitry S. Bezrukov, Daniil Polykovskiy, Rim Shayakhmetov, Andrey Filimonov, et al.

    One of the most important SARS-CoV-2 protein targets for therapeutics is the 3C-like protease (main protease, Mpro). In our previous work1​we used the first Mpro crystal structure to become available, 6LU7. On February 4, 2020 Insilico Medicine released the first potential novel protease inhibitors designed using a ​de novo,​AI-driven generative chemistry approach. Nearly 100 X-ray structures of Mpro co-crystallized both with covalent and non-covalent ligands have been published since then. Here we utilize the recently published 6W63 crystal structure of Mpro complexed with a non-covalent inhibitor and combined two approaches used in our previous study: ligand-based and crystal structure-based. We published 10 representative structures for potential development with 3D representation in PDB format and welcome medicinal chemists for broad discussion and generated output analysis. The molecules in SDF format and PDB-models for generated protein-ligand complexes are available here and at https://insilico.com/ncov-sprint/.​Medicinal chemistry VR analysis was provided by ​Nanome team and the video of VR session is available at ​https://bit.ly/ncov-vr.​


  • Open Access

    Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches

    by Alex Zhavoronkov, Vladimir Aladinskiy, Alexander Zhebrak, Bogdan Zagribelnyy, Victor Terentiev, Dmitry S. Bezrukov, Daniil Polykovskiy, Rim Shayakhmetov, Andrey Filimonov, Philipp Orekhov, et al.

    The emergence of the 2019 novel coronavirus (COVID-19), for which there is no vaccine or any known effective treatment created a sense of urgency for novel drug discovery approaches. One of the most important COVID-19 protein targets is the 3C-like protease for which the crystal structure is known. Most of the immediate efforts are focused on drug repurposing of known clinically-approved drugs and virtual screening for the molecules available from chemical libraries that may not work well. For example, the IC50 of lopinavir, an HIV protease inhibitor, against the 3C-like protease is approximately 50 micromolar, which is far from ideal. In an attempt to address this challenge, on January 28th, 2020 Insilico Medicine decided to utilize a part of its generative chemistry pipeline to design novel drug-like inhibitors of COVID-19 and started generation on January 30th. It utilized three of its previously validated generative chemistry approaches: crystal-derived pocked-based generator, homology modelling-based generation, and ligand-based generation. Novel druglike compounds generated using these approaches were published at www.insilico.com/ncov-sprint/. Several molecules will be synthesized and tested using the internal resources; however, the team is seeking collaborations to synthesize, test, and, if needed, optimize the published molecules.


  • Open Access

    Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches

    by Alex Zhavoronkov, Vladimir Aladinskiy, Alexander Zhebrak, Bogdan Zagribelnyy, Victor Terentiev, Dmitry S. Bezrukov, Daniil Polykovskiy, Rim Shayakhmetov, Andrey Filimonov, Philipp Orekhov, et al.

    The emergence of the 2019 novel coronavirus (2019-nCoV), for which there is no vaccine or any known effective treatment created a sense of urgency for novel drug discovery approaches. One of the most important 2019-nCoV protein targets is the 3C-like protease for which the crystal structure is known. Most of the immediate efforts are focused on drug repurposing of known clinically-approved drugs and virtual screening for the molecules available from chemical libraries that may not work well. For example, the IC50 of lopinavir, an HIV protease inhibitor, against the 3C-like protease is approximately 50 micromolar. In an attempt to address this challenge, on January 28th, 2020 Insilico Medicine decided to utilize a part of its generative chemistry pipeline to design novel drug-like inhibitors of 2019-nCoV and started generation on January 30th. It utilized three of its previously validated generative chemistry approaches: crystal-derived pocked- based generator, homology modelling-based generation, and ligand-based generation. Novel druglike compounds generated using these approaches are being published at www.insilico.com/ncov-sprint/ and will be continuously updated. Several molecules will be synthesized and tested using the internal resources; however, the team is seeking collaborations to synthesize, test, and, if needed, optimize the published molecules.